Management Flashcards

1
Q

2018 NZ Hypertension Guidelines

A

‒ Ideal BP 130/80

‒ ↓ salt, liquorice, weight, ↑ exercise

‒ BP >160/90 Treat

‒ 5y CVD risk > 15%, BP > 130/80 Treat

‒ 5y CVD risk 5 – 15%, BP > 140/90 Discuss

‒ Target BP < 130/80

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Mangement plan based on CV risks

A

Predict 5 yr CV risk Plan

< 5 Life style

5-15 Shared decesion

>15 Treat with meds

BP > 160/100 Treat with meds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

CVD Risk Assessment for people with type 2 diabetes

in New Zealand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The Absolute CVD Risk/Benefit Calculator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Benefit of treatment

A

‒ Systolic BP better predictor of adverse cardiovascular events especially in elderly

‒ Linear increase in risk from BP 115/75

‒↑20mmHg SBP or ↑10mmHg DBP doubles mortality from cardiovascular disease

‒ Benefit of treatment is seen at all age group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

It is essential that HTN is accurately diagnosed in primary careerse effects.

A

Rx of HTN often involves lifelong exposure to multiple medicines and their potential adverse effects

It is recommended that at least 2 BP measurements be taken, at least two minutes apart.

measurements should be taken from both arms.

If the difference between the arms is more than 20 mmHg, the measurements should be repeated.

If this difference persists then subsequent measurements should be taken from the arm with the highest reading.

Consistent differences in BP measurements of > 10 mmHg between arms is associated with increased CVR

Ambulatory or home testing of BP should be considered whenever substantial differences persist between clinic BP measurements to exclude the possibility of “white-coat” HTN (where the pt’s BPe is raised due to the anxiety of having it measured in the clinic).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Life-style modification is always important

A

There are only a limited number of people that can be effectively managed with monotherapy

Start with non-drug therapy if:

  • systolic >140 mmHg
  • and diastolic BP >90 mmHg

Weight reduction (if necessary); for every 1kg loss, SBP gose 1 mmHg down, ie for 10kg = 10 mmHg

Reduced alcohol intake to 1–2 SDs/d (max.)

Reduced sodium intake (avoid excess salt)

Increased exercise

Reduction of particular stress

Smoking cessation

Consider drug factors (e.g. NSAIDs, steroids)

Ensure adequate potassium and calcium intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Excessive salt intake

A

Plays a significant role in HTN as well as contributing to resistant HTN.

Daily salt intake for most people ranges from 9 – 12 g per day.

Reducing salt intake to 5 g/day can achieve a reduction in SBP of 4 – 5 mmHg.

The benefits of salt reduction are greatest for people at increased CVR, e.g. older people and people with diabetes or CKD.

Decreasing the amount of processed food in the diet is the best way to achieve this as approximately 80% of dietary salt is “hidden” in processed food.

The NZ Heart Foundation, https://www.heartfoundation.org.nz/

  • “A guide to heart healthy eating”
  • “The Pacific heartbeat programme”
  • “Know your numbers” tool allows pts to calculate their 5-yr CVR.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Intensification of treatment

A

The main benefits of antihypertensive Rx are due to the BP lowering properties of medicines.

Most people who are being treated for HTN will require multiple medicines and increased doses to achieve Rx targets.

Therefore the decision of when to initiate Rx is more important than which medicine is chosen.

Choice of medicine is also influenced by the presence of co-morbidities and other clinical findings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Goals of treatment (adults)

A

People with: Target BP (mm Hg)

proteinuria >1 g/day (with or without DM) <125/75

coronary heart disease <130/80

diabetes

chronic kidney disease

proteinuria (>300 mg/day)

stroke or TIA

others <140/90

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

If the clinic blood pressure is ≥140/90 mmHg a clinical evaluation should be conducted in order to:

A
  • Confirm a diagnosis of hypertension
  • Assess the pt’s cardiovascular risk
  • Determine if any end organ damage has occurred
  • Detect any causes of secondary hypertension

In pts with severe HTN (SBP ≥180 mmHg or DBP ≥110 mmHg) initiation of Rx should be considered immediately, before the diagnosis of HTN is confirmed, e.g. with ambulatory monitoring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

When to initiate antihypertensive medicines

A

BP ≥160/100 mmHg, i.e. Stage 2 (moderate) or severe HTN

Any pts with HTN who have any of the following factors:

  • Evidence of target organ damage
  • CVD
  • Renal disease
  • Diabetes
  • Five-year CVR ≥15%

Pts aged under 40 yrs with a CVR < 15% with stage one HTN (140 – 160 / 90 – 100 mmHg), who do not have any other criteria for the treatment of HTN, may still require management of BP.

  • Consider referring them for more extensive evaluation for end organ damage, e.g. echocardiogram, and specialist assessment for secondary causes of hypertension.

Pts with isolated SBP, e.g. > 160 mmHg, should be offered the same Rx as people with elevated systolic and DBP.

  • The importance of isolated diastolic HTN is considered to be less than isolated systolic HTN
  • If BP 170/70, should be treated. Egnore the DBP.

Pts with isolated diastolic HTN without significant co-morbidities should be treated according to their overall CVR.

Pts with an intermediate BP level, i.e. between 120 – 139/80 – 89 mmHg, should be encouraged to implement lifestyle measures to control or reduce their BP and prevent being diagnosed with HTN.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Determine whether medications are indicated

A

If office BP ≥ 160 mmHg systolic or ≥ 100 mmHg diastolic (≥ 150/95 on ambulatory or home monitoring) after lifestyle modifications, treat regardless of CVD risk.

If 5‑year CVD risk is high (≥ 15%) and persistent office BP ≥ 130/80 (≥ 125/75 on ambulatory or home monitoring), treat with lifestyle changes and strongly recommend drug treatment.

If 5‑year CVD risk is moderate (5% to 15%) and persistent office BP of ≥ 140/90 (≥ 135/85 on ambulatory or home monitoring), advise lifestyle changes and discuss the risks and benefits of drug treatment.

Be aware that the current New Zealand CVD guidelines are more conservative (i.e., recommend Rx only at higher CVD risk levels) than European/NICE guidelines.

For each 10 mmHg reduction in SBP, there is an approximate 20% relative risk reduction in CVD events over 5 yrs.

Where calculators are available, calculate the absolute risk reduction for individual pts to facilitate shared decision-making.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Individual blood pressure targets

A

BP targets should be individualised according to:

  • pt’s age
  • the presence of co-morbidities.

For uncomplicated HTN:

  • A target of < 140/90 mmHg for people aged
  • > 80 years a target of < 150/90 mmHg

If out-of-clinic monitoring of BP is used:

  • target of < 135/85 mmHg in people < 80 years
  • or < 145/85 mmHg for > 80 years

Pts with CKD, diabetes or CVD aim for a target of < 130/80

  • Lower targets should be approached with caution
  • SBP of < 120 mmHg is associated with serious adverse effects in people with II DM

Alwys check sitting and standing BP in people with DM and elderlies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drug treatment

Monotherapy

A

Start with a single agent at low dose

(depends on the individual and risk factors), e.g.

  • diuretic (preferred in elderly)
  • or β-blocker (cardioselective)

Can use:

  • an ACE inhibitor
  • angiotensin II receptor blocker (ARB)
  • or a calcium channel blocker (CCB) as first line.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hypertension Treatment Choice

A
  • Assess comorbidity.
  • Multiple drugs are usually necessary.
  • Monitor until control achieved
  • Early introduction of 2nd agent
  • Nocte dosing

First Line

  • Thiazides
  • ‒ ACEI/ARB (not cilazapril)
  • ‒ CCB

Second Line - Beta blockers (bisoprolol, carvedilol)

Third Line ‒ Spironolactone ‒ Alpha blockers

17
Q

Recommended starting medication

A
  1. ACE inhibitor or ARB esp. if ≥ 55 years or
  2. Calcium channel blocker (CCB) or low-dose thiazide diuretic (if aged ≥65 years)
  3. If target not reached:
  • ACE1 or ARB + CCB (best evidence) or
  • ACE1 or ARB + thiazide
  1. If target not reached: use combination (best evidence)
    * ACE1/ARB + CCB + thiazide
  2. If still not reached, use spironolactone or seek specialist advice

Need at least 4–6 wks to test effect.

If partly effective, increase dose to maximum or add on.

If ineffective, substitute a different class.

18
Q

Combination (for partly effective monotherapy)

A

Diuretic + β-blocker or ACE inhibitor/ARB

β-blocker + dihydropyridine Ca antagonist

ACE inhibitor/ARB + Ca antagonist

prazosin + others

19
Q

Common combinations of the therapeutic drug classes used for first-line therapy of hypertension.

A

are effective combinations are:

  • A + D
  • B + C
  • B + D

Example start with perindopril 5 mg (o)/d increasing to max 10 mg/d.

If inadequate, add:

  • Indapamide 1.25 mg (o) d or
  • hydrochlorothiazide 12.5 mg (o)/d

Monitor electrolytes, esp. s. potassium.

20
Q

Treatment guidance for primary prevention in pts with HTN

A

Step one treatment for primary prevention in pts with uncomplicated HTN is an ACE inhibitor or calcium channel blocker

Step two treatment, combine an ACE inhibitor or ARB with a calcium channel blocker.

Step three treatment, add a thiazide diuretic e.g. indapamide.

Females of reproductive age should generally not be prescribed an ACE or ARB. Beta-blockers, e.g. metoprolol, or calcium channel blockers, e.g. felodipine, are recommended.

If the pt has diabetes or there is evidence of end organ damage, e.g. LVH, proteinuria, an ACE inhibitor should be prescribed first-line.

Consider a beta-blocker in combination early when:

  • Ischaemic heart disease or heart failure is present – to reduce mortality
  • Atrial fibrillation is present – for rate control

If PVD is present an ACE inhibitor should be considered to slow disease progression, or a calcium channel blocker to vasodilate the peripheral arteries

21
Q

HTN is mostly managed in primary care

A

If hypertensive emergency, seek urgent general medicine advice as admission or urgent assessment may be required.

If hypertensive urgency, treat with oral antihypertensive medication and review daily.

Consider initiating a combination of 2 complementary medications (ACEi or ARB and dihydropyridine CCB) at adequate (non-minimum) doses.

Avoid diuretics, as pts with hypertensive urgency are often hypokalaemic.

Follow up daily to assess BP and clinical features of hypertensive emergency, and to review medications.

Consider slowly increasing interval between follow-ups after BP is

If suspected or confirmed secondary HTN, manage according to suspected cause.

If renal disease is suspected (e.g., signs of RA stenosis, palpable kidneys, suspected urinary obstruction, raised creatinine, family history of kidney disease), investigate and request non-acute nephrology assessment as indicated.

If endocrine disease is suspected, consider non-acute endocrinology assessment.

Develop and maintain a comprehensive management plan:

Advise the pt on lifestyle interventions.

Begin antihypertensive Rx:

  • Check indications for antihypertensive drug Rx based on absolute CVR.
  • Adjust dose to meet appropriate individualised blood pressure targets.

Consider special groups:

  • Hypertension in the elderly
  • Isolated systolic hypertension
  • Hypertension with proteinuria
  • Resistant hypertension

If the patient is pregnant or postpartum, see Hypertension in Pregnancy or Postpartum.

Once blood pressure is satisfactory, review every 6 months.

Request non-acute general medicine assessment if:

  • resistant HTN ( > 140/90 despite good adherence to maximally tolerated triple anti‑hypertensive Rx).
  • age
  • suspicion of secondary cause.
  • uncertain whether drug treatment should be initiated.

Request written general medicine advice if referral criteria is not met, but clinical concern remains.

22
Q

Hypertension in the elderly

A

Clinical trials in the elderly consistently show benefit from antihypertensive therapy, including in patients aged > 80 years.

Provide close follow-up to identify treatment-related adverse effects, including:

  • hypotension
  • Postural hypotension ( esp Thiazide)
  • syncope
  • electrolyte abnormalities
  • acute kidney injury

In frail elderly pts, use clinical judgement and consider risks of Rx e.g., orthostatic hypotension, falls, polypharmacy, and interactions.

23
Q

Isolated systolic hypertension

A

Pts with isolated systolic HTN, e.g. > 160 mmHg, should be offered the same Rx as people with elevated systolic and DBP

Predominantly a problem in older pts.

Use first-line diuretics or calcium channel blockers.

Pts with isolated diastolic HTN without significant co-morbidities should be treated according to their overall cardiovascular risk. The importance of isolated diastolic HTN is considered to be less than isolated systolic HTN

24
Q

Hypertension with proteinuria

A

HTN is a driver for progressive renal failure in CRD.

Use ACE inhibitor or ARB and titrate to the maximum tolerated dose.

Consider a lower SBP target of 25 (males) or > 35 (females).

Monitor eGFR in these groups.

25
Q

Resistant hypertension

A

Defined as failure to achieve target despite appropriate lifestyle measures and 3 drugs from different classes, including a diuretic, at adequate doses.

Exclude:

  • non-adherence
  • white-coat HTN
  • use of incorrectly sized BP cuffs.

Use a multi-modal approach:

Check ambulatory or home BPs.

Review lifestyle interventions for unaddressed factors.

Ensure a secondary cause has not been missed, particularly underlying renal disease.

If resistant HTN confirmed, request non-acute general medicine assessment and consider a trial of spironolactone 12.5 to 25 mg daily, with appropriate monitoring of electrolytes and creatinine.

Spironolactone is twice as effective in this setting compared with beta blockers or long-acting alpha-blockers, with approximately 8 versus 4 mmHg reductions respectively.

Watch for hyperkalaemia.

If not reaching Rx targets despite Rx with 3 concurrent medications at adequate doses (or unacceptable side‑effects), request non-acute general medicine assessment.

Invasive treatments (e.g., renal denervation) cannot be recommended outside of specialist centres.

26
Q

Important Hints

A

It is hard to have BP controlled especially with one agent only; usually need 2 or more agents

Start with Thiazides first, then ACI, then ARB, then B-blockers

Give combination of small doses of antihypertensive Rx:

  • better synergetic effect than increasing the dose of a single agent

If any side effects of a single agent, move out of the same class

If coughs to ACU, move to Ca++ channel blockers

Amlodipine has the least side ankle oedema S/E among the other Ca++ channel blockers

Bisoprolol and Carvedilol are far better than Atenolol and Metoprolol

Doxazosin increases the risk of Ht failure unless you have other reasons and used the other agents first

Do not give Ca++ channel blockers to pregnant ladies

HTN in elderly is characterised with low rennin activity and therefore CCB and thiazide should be used first

Losartan if good for Gout

27
Q

Hypertension with Diabetes

A

Target BP < 130/80

Agents of Choice:ACEI or ARBs (high dose)

Bendrofluazide 2.5mg/ Chlorthalidone 25mg – minimal effect on blood sugar

Thiazide + Beta blocker = ↑ diabetes

28
Q

Hypertension update: beyond cilazapril-plus lecture